Efficacy and safety of zonisamide: results of a multicenter study

Leppik, Ilo E.; Willmore, L. James; Homan, Richard W.; Fromm, Gerhard H.; Oommen, Kalarickal J.; Penry, J. Kiffin; Sackellares, J. Chris; Smith, Dorothy B.; Lesser, Ronald P.; Wallace, Jan D.; Trudeau, Judith; LaMoreaux, L.; Spenser, M.

doi:10.1016/0920-1211(93)90021-x

Cited by 134 publications

(64 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subjects completing the 16 weeks were permitted to continue and alterations in other AEDs were permitted after the initial study period. A total of 113 subjects entered the longer period and 76 patients continued for more than 1 year (41). The median daily dose of ZNS was 500 mg (range 50-1,100 mg).…”

Section: Efficacy In Localization-related Epilepsiesmentioning

confidence: 99%

Zonisamide

Leppik

1999

Epilepsia

View full text Add to dashboard Cite

Summary: Zonisamide (ZNS) is a broad-spectrum antiepileptic drug in both animal models of epilepsy and patients with epilepsy. It is effective for both localization-related and generalized epilepsies and appears to be particularly potent in progressive myoclonic epilepsy syndromes. Its pharmokinetic profile is favorable, with a long half-life and low protein binding.However, its insolubility may make the development of a parenteral formulation difficult. Its safety profile is good, although teratogenicity in animal models is of concern. Adult doses of 400-600 mg per day in two doses, with blood levels from 20 to 30 mg/ml, appear to be effective.

show abstract

Section: Efficacy In Localization-related Epilepsiesmentioning

confidence: 99%

Zonisamide

Leppik

1999

Epilepsia

View full text Add to dashboard Cite

show abstract

“…Among the various AEDs, acetazolamide [4], zonisamide [3], topiramate [2], and felbamate [5] are well known causes. Although crystalluria does not always indicate urolithiasis, it is frequently associated and may be useful in the diagnosis of urolithiasis if crystalluria is persistent and of a specific type [1].…”

mentioning

confidence: 99%

Effect of antiepileptic drug monotherapy on crystalluria in children and young adults

2003

Journal of Neurology

View full text Add to dashboard Cite

“…Zonisamide is effective for localization-related epilepsies [49]. Protein binding is approximately 40 % and its major elimination pathway is hepatic as a substrate of CYP3A4.…”

Section: Zonisamidementioning

confidence: 99%

Medical Management of Seizures in Cerebrovascular Disorders

Menon

Leppik

2015

Seizures in Cerebrovascular Disorders

View full text Add to dashboard Cite

Cerebrovascular disorders are one of the most common identifiable causes of epilepsy, especially in the elderly [1]. Seizures after a stroke can occur early, within 7-14 days [2-6], or late, after 14 days [7][8][9][10]. Early seizures do not necessarily progress to epilepsy, but may result in increased morbidity and mortality. Reports vary considerably regarding the incidence of single seizures and epilepsy after a stroke. In adults younger than 50 years of age, 12.7 % with ischemic strokes and 25.6 % with intracranial hemorrhage developed epilepsy. This study used the more recent definition of epilepsy, which is the occurrence of a single seizure associated with an enduring condition associated with epilepsy. Another large study reported the occurrence of seizures in 168 (8.9 %) of 1897 persons following an ischemic stroke and 28 (10.6 %) of 265 after a hemorrhagic stroke [4]. Most seizures occurred within 2 years of the stroke.A critical question addressing the issue of treatment is the occurrence of a second seizure after a single seizure. Unfortunately, this is a difficult question to answer from the literature. Many physicians initiate treatment with antiepileptic drugs (AEDs) following a single seizure because of the perception that there is a high risk of additional seizures in the context of stroke and seizure. Thus, reports of recurrent seizures are confounded with treatment, and it is difficult to establish the risk of epilepsy as defined by two or more unprovoked seizures. In one study by Arntz, 75 % of persons with an ischemic stroke and 80 % with a hemorrhagic stroke were

show abstract

Efficacy and safety of zonisamide: results of a multicenter study

Cited by 134 publications

References 8 publications

Zonisamide

Zonisamide

Effect of antiepileptic drug monotherapy on crystalluria in children and young adults

Medical Management of Seizures in Cerebrovascular Disorders

Contact Info

Product

Resources

About